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Abstract 
Achalasia is a neurodegenerative motility disorder of 
the oesophagus resulting in deranged oesophageal per-
istalsis and loss of lower oesophageal sphincter func-
tion. Historically, annual achalasia incidence rates were 
believed to be low, approximately 0.5-1.2 per 100000. 
More recent reports suggest that annual incidence 
rates have risen to 1.6 per 100000 in some popula-
tions. The aetiology of achalasia is still unclear but is 
likely to be multi-factorial. Suggested causes include 
environmental or viral exposures resulting in inflamma-
tion of the oesophageal myenteric plexus, which elicits 
an autoimmune response. Risk of achalasia may be el-
evated in a sub-group of genetically susceptible people. 
Improvement in the diagnosis of achalasia, through the 
introduction of high resolution manometry with pres-
sure topography plotting, has resulted in the develop-
ment of a novel classification system for achalasia. This 
classification system can evaluate patient prognosis 
and predict responsiveness to treatment. There is cur-
rently much debate over whether pneumatic dilatation 
is a superior method compared to the Heller’s myotomy 
procedure in the treatment of achalasia. A recent com-
parative study found equal efficacy, suggesting that 
patient preference and local expertise should guide the 
choice. Although achalasia is a relatively rare condition, 
it carries a risk of complications, including aspiration 
pneumonia and oesophageal cancer. The risk of both 
squamous cell carcinoma and adenocarcinoma of the 
oesophagus is believed to be significantly increased in 
patients with achalasia, however the absolute excess 
risk is small. Therefore, it is currently unknown whether 
a surveillance programme in achalasia patients would 
be effective or cost-effective. 
© 2013 Baishideng. All rights reserved.
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Core tip: Achalasia remains a disease of unknown ae-
tiology. Multicentre studies could help elucidate the 
cause, especially as it presents with a similar phenotype 
to Chagas disease which is much better understood. 
Improved understanding of aetiology could guide novel 
treatments. Current treat choice in fit patients lies be-
tween pneumatic dilatation and laparoscopic Heller’s 
myotomy. Botulinum toxin is appropriate and effective 
for those unfit for other intervention. Novel treatments 
such as metal stents and natural orifice surgery are be-
ing trialled. 
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INTRODUCTION
Achalasia is a motility disorder of  the oesophagus, of  
unknown aetiology, which results in degeneration of  the 
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myenteric nerve plexus of  the oesophageal wall. The 
resultant abnormalities and diagnostic characteristics 
of  achalasia include loss of  oesophageal peristalsis and 
failure of  relaxation of  the lower oesophageal sphincter, 
particularly during swallowing[1].
DIAGNOSIS
Dysphagia is the cardinal symptom of  achalasia. Diag-
nosis requires a high index of  suspicion and exclusion 
of  other causes. Diagnosis is confirmed by manometric, 
endoscopic and radiographic investigations. Oesophageal 
manometry is regarded as the gold standard in the diag-
nosis of  achalasia, classically showing aperistalsis and fail-
ure of  relaxation of  the lower oesophageal sphincter[2], 
as shown in Figure 1. Endoscopy is not accurate in the 
diagnosis of  achalasia. However, it is still necessary to ex-
clude a carcinoma at the lower end of  the oesophagus[3]. 
Barium esophagogram can often show the pathogno-
monic “bird’s beak” appearance of  the distal oesophagus 
with dilatation of  the oesophagus proximally (Figure 2). 
However, this is often a finding in established disease and 
therefore a normal barium swallow does not rule out the 
diagnosis of  achalasia. With the introduction of  high res-
olution manometry, together with pressure topography, 
plotting the diagnosis of  achalasia can now be classified 
into three subtypes; type 1 classic achalasia, type 2 achala-
sia with compression and pressurisation effects, and type 
3 spastic achalasia[4]. This classification process can aid 
treatment decisions, with type 2 achalasia being the most 
responsive to pneumatic dilatation, Hellers myotomy and 
botulinum toxin and therefore having the best outcome[5]. 
Oesophageal emptying is determined by the distensibility 
of  the oesophago-gastric junction. This can be assessed 
using an endoscopic functional luminal imaging probe 
(EndoFLIP). Recently, Dutch and American groups 
have demonstrated that this novel technique is a better 
predictor than lower oesophageal sphincter pressure for 
assessing response to treatment in achalasia, both symp-
tomatically and when measured by gastric emptying by 
oesophageal emptying[6,7]. 
PATHOGENESIS
The pathogenesis of  achalasia is not well understood 
but it is believed to be due to an inflammatory neuro-
degenerative insult with possible viral involvement. The 
measles and herpes viruses have been suggested as candi-
date viruses however molecular techniques have failed to 
confirm these claims and therefore the causative agent re-
mains undiscovered[8]. Genetic and autoimmune compo-
nents have also been suggested as origins of  the neuronal 
damage however research to date has not found the exact 
cause[9]. Inflammatory changes within the oesophagus 
following the causative insult result in the loss of  post-
ganglionic inhibitory neurons in the myenteric plexus and 
a consequent reduction in the inhibitory transmitters, ni-
tric oxide and vasoactive intestinal peptide. The excitatory 
neurons remain unaffected, with the resulting imbalance 
between excitatory and inhibitory neurons preventing 
lower oesophageal sphincter relaxation[10]. Lack of  peri-
stalsis and a non-relaxing lower oesophageal sphincter 
cause progressive dysphagia. Regurgitation, particularly 
at night, with aspiration of  undigested food and weight 
loss can be presenting features, particularly in established 
disease. Features which present in the early stages of  the 
disease may be similar to that of  gastro-oesophageal re-
flux, including retrosternal chest pain typically after eating 
and heartburn[11]. Due to initial non-specific symptoms 
in early stage disease and the low prevalence of  achalasia 
worldwide, the condition often goes undiagnosed for 
many years, giving rise to features of  late stage disease 
and their associated complications. 
EPIDEMIOLOGY
Achalasia is a relatively rare condition. A summary of  
studies published to date on achalasia incidence and 
prevalence is shown in Table 1[12-25]. The incidence of  
achalasia varied between studies, with reports as low as 
0.03/100000 per year in Zimbabwe[22] to 1.63/100000 
per year in Canada[14]. The majority of  incidence rates re-
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Figure 1  Oesophageal manometry demonstrating simultaneous con-
tractions within the oesophagus and a non-relaxing lower oesophageal 
sphincter.
Dilated oesophagus 
with fluid level
Tight “Bird’s Beak” lower 
oesophageal sphincter
Stomach 
Figure 2  Barium swallow demonstrating typical “bird’s-beak” appearance 
of the lower oesophageal sphincter in achalasia. The oesophagus above 
this is dilated.
ported clustered between 0.5-1.2 per 100000/year (Table 
1). In an attempt to investigate changing incidence rates 
over time, we plotted incidence rates against the mid-
timepoint within the study periods (Figure 3). As shown 
in Figure 3, incidence rates of  achalasia appear to be ris-
ing, with most reports since the 1980s exceeding rates of  
0.8/100000 per year, which has doubled to 1.6/100000 
per year in post-2000 studies. Whether this reflects a true 
rise in incidence, or greater awareness and improved diag-
nosis of  the condition remains uncertain though.
There are no distinct patterns of  achalasia incidence 
in terms of  age and sex distribution; it can affect both 
genders, all races and all ages[26]. A few studies have sug-
gested a bimodal distribution of  incidence by age, with 
peaks at around age 30 and 60 years[12,18,24], while others 
have pointed towards a generally increased risk of  acha-
lasia with increased age[15,23,25]. Achalasia appears to affect 
males and females to largely equal extents[12,13,15,18,21,23-25,27] 
although some investigations have detected slightly high-
er rates amongst females[16,19,28]. Only one study reported 
a higher achalasia incidence in men[14]. A study carried 
out by Mayberry et al[15] found achalasia to be significantly 
more common in the Republic of  Ireland in comparison 
to its neighbouring countries (Table 1). Similarly, a study 
which reviewed the incidence of  achalasia in New Zea-
land found differing incidence between ethnic groups[21]. 
The Pacific Islanders had an incidence of  1.3/100000 per 
year in comparison to those of  Maori descent having an 
incidence of  0.2/100000 per year. This may reflect the 
influence of  genetic factors in achalasia aetiology[21].
A Canadian population-based study also considered 
the prevalence and survival rates of  patients with achala-
sia[14]. Sadowski et al[14] found that the prevalence of  acha-
lasia rose from 2.51/100000 in 1996 to 10.82/100000 in 
2007, despite a relatively stable incidence over the same 
time period (Table 1). The rise in prevalence was seen in 
both genders but was noted to be more pronounced in 
males, reflecting the fact that achalasia is a slowly progres-
sive disease. This rise in prevalence was also evident in 
an Israeli study[18] and was noted in an Icelandic study be-
tween 1952 and 2002[13]. It is interesting to note that the 
Canadian study observed survival of  achalasia patients to 
be significantly lower than the age-sex matched control 
population[14]. However, others have discerned that the 
majority of  deaths in achalasia patients result from un-
related causes, leading to an equivalent life expectancy to 
the general population[29].
AETIOLOGY
There has been much debate over the aetiology of  acha-
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  Study Location Years studied Total number of Prevalence rate Incidence rate 
achalasia patients (per 100000) (per 100000/year)
  Howard et al[12] Edinburgh, Scotland 1986-1991 Not reported Not reported   0.81
  Birgisson et al[13] Iceland 1952-2002   62 8.7   0.55
  Sadowski et al[14] Alberta, Canada 1995-2008 463     2.518 Not reported
  10.829    1.639
  Mayberry et al[15] Great Britain and Ireland 1972-1983                6306 Not reported Not reported
 Scotland 583                       11.2        1.1-1.26
 Wales 197 7.1 Not reported
 Northern Ireland 153 9.8 Not reported
 Republic of Ireland 453                       13.4 Not reported
 England                4920                       10.8   0.97
  Mayberry et al[16] Cardiff, Wales 1926-1977   48 Not reported 0.4
  Mayberry et al[17] Nottingham, England 1966-1983   53                         8.0   0.51
  Arber et al[18] Israel 1973-1983 162   7.91   0.83
                     12.62    1.154
  Earlam et al[19] Rochester, United States 1925-1964   11 Not reported 0.6
  Galen et al[20] Virginia, United States 1975-1980   31 Not reported 0.6
  Mayberry et al[21] New Zealand 1980-1984 152 Not reported                           1.0
  Stein et al[22] Zimbabwe 1974-1983   25 Not reported   0.03
  Farrukh et al[23] Leicester, England 1986-2005   14 Not reported    0.895
  Ho et al[24] Singapore 1989-1996   49   1.77   0.29
  Gennaro et al[25] Veneto, Italy 2001-2005 365 Not reported   1.59
Table 1  Summary of epidemiological studies of achalasia incidence and prevalence in adults
1Rate in 1973 only; 2Rate in 1983 only; 3Rate between 1973-1978; 4Rate between 1979-1983 only; 5Rate only applicable for South Asian population of region; 
6Rate reported as 1.1 for men and 1.2 for women; 7Rate only applicable to Oxford region of England; 8Rate in 1996 only; 9Rate in 2007 only.
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Figure 3  Achalasia incidence by mid-study time points.
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with other genetic diseases including Parkinson’s dis-
ease, Downs syndrome and MEN2B syndrome[10]. One 
recent suggested the possibility of  involvement of  the 
rearranged during transfection gene, which is a major 
susceptibility gene for Hirschprung’s disease (also linked 
with Down’s syndrome)[9]. Mayberry et al[38] conducted a 
study of  first degree relatives of  achalasia patients but 
concluded that inheritance was unlikely to be a signifi-
cant causative factor due to the rarity of  familial cases 
and exposure to common environmental and social fac-
tors within a family group may explain the presence of  
familial cases of  achalasia.
It has been postulated that achalasia may incorporate 
a multi-factorial aetiology with an initiating event such as 
a viral or environmental insult resulting in oesophageal 
myenteric plexus inflammation. This inflammatory reac-
tion may then initiate an autoimmune response in a sus-
ceptible group of  genetically predisposed people, causing 
destruction of  inhibitory neurons[39].
TREATMENT
The mainstay of  treatment for achalasia is either pneu-
matic balloon dilatation or laparoscopic myotomy[40]. 
In pneumatic balloon dilatation, a balloon is positioned 
across the lower oesophageal sphincter and inflated, ef-
fectively rupturing the muscle of  the affected segment. 
Surgical myotomy can be performed as either an open 
or laparoscopic procedure. The laparoscopic technique 
is now the most commonly performed. The procedure 
involves making a longitudinal division of  the circular 
muscle of  the lower oesophageal sphincter, extending 
this both proximally and distally onto the cardia[11]. Many 
surgeons advise the use of  an anti-reflux procedure to-
gether with surgical myotomy, as these patients at are 
an increased risk of  reflux following surgery[3]. A recent 
study compared partial anterior and partial posterior fun-
doplication following cardiomyotomy. It concluded that 
partial posterior fundoplication was superior to the ante-
rior procedure due to significantly lower reintervention 
rates for postoperative dysphagia[41].
The best comparative study between pneumatic dila-
tation and surgery to date has demonstrated remarkably 
similar outcomes in matched patients over a three year 
follow up period[42]. Therapeutic success at two years was 
noted in 86% of  those treated by pneumatic dilatation 
and 90% of  those who had laparoscopic Heller’s my-
otomy. The regimen for pneumatic dilatation was rigorous 
with the option of  multiple dilatations. The accompany-
ing editorial suggests that choice should be determined 
by patient preference and local expertise[43]. A new endo-
scopic esophagomyotomy technique has been recently in-
troduced: Peroral endoscopic myotomy involves dividing 
the inner circular muscle of  the oesophagus. This requires 
sophisticated expertise and remains experimental[39].
In patients for whom invasive procedures are not 
suitable, alternative treatment options may be considered 
including pharmacological intervention using long-acting 
lasia, with several potential triggers for the inflammatory 
destruction of  inhibitory neurons in the oesophageal 
myenteric plexus being implicated. These include autoim-
mune responses, infectious agents and genetic factors.
Auto-immune conditions
One recent study observed that patients with achalasia were 
3.6 times more likely to suffer an autoimmune condition, 
compared with the general population[30]. Sjogren’s syn-
drome, Systemic Lupus Erythematosus and uveitis were 
all significantly more prevalent in achalasia patients. The 
study also found the presence of  a T-cell infiltrate and 
antibodies within the myenteric plexus of  many patients 
with achalasia and an increased presence of  human leu-
kocyte antigen class Ⅱ antigens[30]. Another study noted 
an overall higher prevalence of  neural autoantibodies 
in patients with achalasia in comparison with a healthy 
control group[31]. Although no specific autoantibody was 
identified, this further supports the theory that achalasia 
has an autoimmune basis[31].
Infectious agents
The role of  an infectious agent in the development 
of  achalasia has been widely debated with several viral 
agents being implicated. For example, Chagas disease 
has a known infectious aetiology, and exhibits many 
similarities with achalasia[32]. In addition, there are sev-
eral reports of  varicella zoster virus and Guillain-Barre 
syndrome preceding the onset of  achalasia[32]. Antibody 
studies have demonstrated increased titres to herpes and 
measles viruses in patients with achalasia in comparison 
to healthy control groups[33,34]. One study looking specifi-
cally at the link between the herpes simplex virus (HSV) 
and primary achalasia indicated the presence of  HSV-1 
reactive immune cells in the lower oeseophageal sphinc-
ter of  achalasia patients, suggesting that HSV-1 may be 
involved in the neuronal damage to the myenteric plexus 
leading to achalasia[35]. A further study of  peripheral 
blood immune cells found that patients with achalasia 
showed an enhanced response to HSV-1 antigens[34]. In 
contrast, another investigation using PCR on myotomy 
specimens did not find any association between herpes, 
measles or human papilloma viruses and achalasia[36]. 
The current evidence for a causative infectious agent is 
contradictory and no clear causal relationship has yet 
been established.
Genetic predisposition
The genetic basis for achalasia has not been widely inves-
tigated due to its low prevalence. One syndrome, known 
as the triple “A” syndrome, which consists of  a triad of  
achalasia, alacrima and adrenocorticotrophic hormone 
resistant adrenal insufficiency is a known autosomal 
recessive disorder caused by gene mutations on chromo-
some 12. This syndrome, together with the prevalence 
of  cases within children of  consanguineous couples[37], 
suggests the possibility for a genetic component to the 
aetiology of  achalasia. There have been associations 
O’Neill OM et al . Achalasia: A clinical and epidemiological review
5810 September 21, 2013|Volume 19|Issue 35|WJG|www.wjgnet.com
nitrates and calcium channel blockers. However, these 
are of  limited benefit[44]. A further option is botulinum 
toxin injection into the lower oesophageal sphincter. 
This technique offers good short term results[45]. Most 
recently, metal stents have been used successfully[46]. Both 
of  these options are generally only suited to those with 
several co-morbidities[9].
COMPLICATIONS
Patients with achalasia are at risk of  developing the com-
plications associated with disease progression as well as 
its treatment interventions. The complications of  acha-
lasia that can develop as a result of  the natural course of  
the condition include aspiration-pneumonia[47]. Mega-
esophagus develops in 10% of  inadequately treated cases 
and can ultimately require oesophagectomy[48]. 
Squamous cell carcinoma is the most common oe-
sophageal cancer in patients with achalasia and this is 
thought to result from the high level of  nitrosamines 
produced by bacterial overgrowth due to stasis in the 
oesophagus leading to chronic inflammation and dyspla-
sia[49]. There is considerable variation in the documented 
oesophageal cancer risk in achalasia. One review found 
that the prevalence of  oesophageal cancer in achalasia 
was 3%, corresponding to a 50-fold increased risk[50], 
while a prior review reported increased risks ranging 
from 0-33-fold greater than the general population[51]. 
Subsequent reports would also indicate a slightly more 
modest, but still significantly elevated, risk of  oesopha-
geal cancer 16-28-times greater than an age-sex matched 
control population[52,53].
The risk of  oesophageal adenocarcinoma is also 
increased in those with achalasia and may be a complica-
tion of  longstanding reflux following successful inter-
ventional treatment[27,54]. A recent publication from The 
Netherlands demonstrated that 8.2% of  331 primary 
achalasia patients developed Barrett’s oesophagus over a 
period of  up to 25 years[55]. Two of  these Barrett’s cases 
progressed to develop oesophageal adenocarcinoma. 
Other studies have also reported elevated risks of  Bar-
rett’s oesophagus and oesophageal adenocarcinoma in 
achalasia patients[27,56].
A few studies have described even larger increased 
risks of  oesophageal cancer amongst achalasia patients. 
One German study reported an risk of  developing oe-
sophageal cancer up to 140 times greater in patients with 
achalasia than the normal population[57], which is equiva-
lent to cancer risk in Barrett’s oesophagus[58]. Further-
more, oesophageal cancer diagnosis in achalasia patients 
is often delayed, contributing to a poor mean survival af-
ter diagnosis of  only 0.7 years[53,59]. These findings would 
support the need for endoscopic surveillance in achalasia 
patients.
However, despite the relative risk being increased, the 
absolute risk of  cancer in patients with achalasia is still 
small and there would be a large number of  examina-
tions required to detect a single cancer. In fact it has been 
estimated that for the detection of  a single cancer there 
would need to be 681 endoscopic examinations undertak-
en[53]. Despite the potential complications associated with 
diagnosis, treatments and increased cancer risk, achalasia 
patients don’t experience a significant compromise to 
overall life expectancy[29]. The most recent guidelines in-
dicate that surveillance endoscopy is not indicated[60].
CONCLUSION
In conclusion, achalasia remains a relatively under-
researched condition with many details on aetiology, 
true incidence, and risk of  complications still unknown. 
There has been some progress over the past years into 
the aetiology of  the condition but there is a need for fur-
ther research to be carried out into this field to establish 
causative agents. Furthermore, clarification in relation to 
the need for an endoscopic screening program in patients 
with achalasia to detect the development of  oesophageal 
cancer is required. 
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